Influenza vaccines: new developments
Identifieur interne : 001870 ( Main/Exploration ); précédent : 001869; suivant : 001871Influenza vaccines: new developments
Auteurs : Guus F. Rimmelzwaan [Pays-Bas] ; Albert D. M. E Osterhaus [Pays-Bas]Source :
- Current Opinion in Pharmacology [ 1471-4892 ] ; 2001.
Descripteurs français
- Wicri :
- topic : Pharmacologie.
English descriptors
- KwdEn :
- Teeft :
- Adjuvant, Adme, Animal models, Antibody responses, Antibody titers, Antigen delivery systems, Antigen presentation, Antigenic, Antigenic drift, Antigenic variation, Attenuated, Blackwell science, Clinical trials, Conventional vaccines, Current influenza vaccines, Current vaccines, Developments rimmelzwaan, Drift variants, Elderly patients, Elsevier science, Embryonated, Embryonated chicken eggs, Epidemic strain, Epidermal immunization, Gene segments, Hong kong, Human influenza, Human population, Immune responses, Immunogenicity, Influenza, Influenza epidemics, Influenza season, Influenza vaccine, Influenza vaccine preparation, Influenza vaccines, Influenza virus, Influenza virus vaccines, Influenza viruses, Intramuscular injection, Intranasal influenza virus vaccine, Iscom, Iscom vaccines, Laboratory strain, Lipid bilayer, Mdck, Mdck cells, Membrane glycoproteins, More immunogenic, Natural infection, Novel adjuvants, Novel vaccine production technologies, Osterhaus, Osterhaus adme, Other viruses, Pandemic, Pandemic influenza, Phenotype, Plasmid, Potential risk, Proc natl acad, Protective immunity, Reassortant, Reassortant virus, Reassortant viruses, Reference strain, Rimmelzwaan, Runny nose, Serum antibody response, Sore throat, Split vaccines, Strong responses, Subtype, Subunit, Subunit vaccines, Vaccination, Vaccine, Vaccine immunogenicity, Vaccine preparations, Vaccine strains, Viral, Viral antigen, Viral antigens, Viral protein, Viral proteins, Virus, Virus neutralizing antibodies, World health organization.
Abstract
Abstract: Current inactivated influenza vaccines are being produced with three influenza virus strains that are recommended annually by the World Health Organization on the basis of information obtained from global influenza surveillance. The use of these vaccines, for which the antigens are produced in embryonated chicken eggs, can result in a significant reduction of influenza-related morbidity and mortality. Nevertheless, there is still a demand for vaccines with a higher efficacy that can be produced more rapidly and more flexibly in response to an epidemic or a pandemic. New developments in the field of influenza vaccine preparation include novel vaccine production technologies, reverse genetics technology for the generation of vaccine strains and novel adjuvants for the improvement of vaccine immunogenicity.
Url:
DOI: 10.1016/S1471-4892(01)00085-6
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001598
- to stream Istex, to step Curation: 001598
- to stream Istex, to step Checkpoint: 000697
- to stream Main, to step Merge: 001910
- to stream Main, to step Curation: 001870
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Influenza vaccines: new developments</title><author><name sortKey="Rimmelzwaan, Guus F" sort="Rimmelzwaan, Guus F" uniqKey="Rimmelzwaan G" first="Guus F" last="Rimmelzwaan">Guus F. Rimmelzwaan</name></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E" last="Osterhaus">Albert D. M. E Osterhaus</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AFA3DF8A8A2D1888244C2CE1DBDD7BBE6F692A82</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1016/S1471-4892(01)00085-6</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-3MSHXND1-2/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001598</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001598</idno><idno type="wicri:Area/Istex/Curation">001598</idno><idno type="wicri:Area/Istex/Checkpoint">000697</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000697</idno><idno type="wicri:doubleKey">1471-4892:2001:Rimmelzwaan G:influenza:vaccines:new</idno><idno type="wicri:Area/Main/Merge">001910</idno><idno type="wicri:Area/Main/Curation">001870</idno><idno type="wicri:Area/Main/Exploration">001870</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Influenza vaccines: new developments</title><author><name sortKey="Rimmelzwaan, Guus F" sort="Rimmelzwaan, Guus F" uniqKey="Rimmelzwaan G" first="Guus F" last="Rimmelzwaan">Guus F. Rimmelzwaan</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Institute of Virology, National Influenza Center, Erasmus University Rotterdam, Dr Molewaterplein 50, 3015 GE Rotterdam</wicri:regionArea><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Pays-Bas</country></affiliation></author><author><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E" last="Osterhaus">Albert D. M. E Osterhaus</name><affiliation wicri:level="1"><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>Institute of Virology, National Influenza Center, Erasmus University Rotterdam, Dr Molewaterplein 50, 3015 GE Rotterdam</wicri:regionArea><wicri:noRegion>3015 GE Rotterdam</wicri:noRegion></affiliation><affiliation wicri:level="1"><country wicri:rule="url">Pays-Bas</country></affiliation></author></analytic><monogr></monogr><series><title level="j">Current Opinion in Pharmacology</title><title level="j" type="abbrev">COPHAR</title><idno type="ISSN">1471-4892</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2001">2001</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">5</biblScope><biblScope unit="page" from="491">491</biblScope><biblScope unit="page" to="496">496</biblScope></imprint><idno type="ISSN">1471-4892</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1471-4892</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Pharmacology</term><term>Virology</term><term>adjuvant</term><term>influenza virus</term><term>production technology</term><term>protective immunity</term><term>vaccine</term></keywords><keywords scheme="Teeft" xml:lang="en"><term>Adjuvant</term><term>Adme</term><term>Animal models</term><term>Antibody responses</term><term>Antibody titers</term><term>Antigen delivery systems</term><term>Antigen presentation</term><term>Antigenic</term><term>Antigenic drift</term><term>Antigenic variation</term><term>Attenuated</term><term>Blackwell science</term><term>Clinical trials</term><term>Conventional vaccines</term><term>Current influenza vaccines</term><term>Current vaccines</term><term>Developments rimmelzwaan</term><term>Drift variants</term><term>Elderly patients</term><term>Elsevier science</term><term>Embryonated</term><term>Embryonated chicken eggs</term><term>Epidemic strain</term><term>Epidermal immunization</term><term>Gene segments</term><term>Hong kong</term><term>Human influenza</term><term>Human population</term><term>Immune responses</term><term>Immunogenicity</term><term>Influenza</term><term>Influenza epidemics</term><term>Influenza season</term><term>Influenza vaccine</term><term>Influenza vaccine preparation</term><term>Influenza vaccines</term><term>Influenza virus</term><term>Influenza virus vaccines</term><term>Influenza viruses</term><term>Intramuscular injection</term><term>Intranasal influenza virus vaccine</term><term>Iscom</term><term>Iscom vaccines</term><term>Laboratory strain</term><term>Lipid bilayer</term><term>Mdck</term><term>Mdck cells</term><term>Membrane glycoproteins</term><term>More immunogenic</term><term>Natural infection</term><term>Novel adjuvants</term><term>Novel vaccine production technologies</term><term>Osterhaus</term><term>Osterhaus adme</term><term>Other viruses</term><term>Pandemic</term><term>Pandemic influenza</term><term>Phenotype</term><term>Plasmid</term><term>Potential risk</term><term>Proc natl acad</term><term>Protective immunity</term><term>Reassortant</term><term>Reassortant virus</term><term>Reassortant viruses</term><term>Reference strain</term><term>Rimmelzwaan</term><term>Runny nose</term><term>Serum antibody response</term><term>Sore throat</term><term>Split vaccines</term><term>Strong responses</term><term>Subtype</term><term>Subunit</term><term>Subunit vaccines</term><term>Vaccination</term><term>Vaccine</term><term>Vaccine immunogenicity</term><term>Vaccine preparations</term><term>Vaccine strains</term><term>Viral</term><term>Viral antigen</term><term>Viral antigens</term><term>Viral protein</term><term>Viral proteins</term><term>Virus</term><term>Virus neutralizing antibodies</term><term>World health organization</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Pharmacologie</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: Current inactivated influenza vaccines are being produced with three influenza virus strains that are recommended annually by the World Health Organization on the basis of information obtained from global influenza surveillance. The use of these vaccines, for which the antigens are produced in embryonated chicken eggs, can result in a significant reduction of influenza-related morbidity and mortality. Nevertheless, there is still a demand for vaccines with a higher efficacy that can be produced more rapidly and more flexibly in response to an epidemic or a pandemic. New developments in the field of influenza vaccine preparation include novel vaccine production technologies, reverse genetics technology for the generation of vaccine strains and novel adjuvants for the improvement of vaccine immunogenicity.</div></front></TEI><affiliations><list><country><li>Pays-Bas</li></country></list><tree><country name="Pays-Bas"><noRegion><name sortKey="Rimmelzwaan, Guus F" sort="Rimmelzwaan, Guus F" uniqKey="Rimmelzwaan G" first="Guus F" last="Rimmelzwaan">Guus F. Rimmelzwaan</name></noRegion><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E" last="Osterhaus">Albert D. M. E Osterhaus</name><name sortKey="Osterhaus, Albert D M E" sort="Osterhaus, Albert D M E" uniqKey="Osterhaus A" first="Albert D. M. E" last="Osterhaus">Albert D. M. E Osterhaus</name><name sortKey="Rimmelzwaan, Guus F" sort="Rimmelzwaan, Guus F" uniqKey="Rimmelzwaan G" first="Guus F" last="Rimmelzwaan">Guus F. Rimmelzwaan</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/H2N2V1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001870 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001870 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= H2N2V1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:AFA3DF8A8A2D1888244C2CE1DBDD7BBE6F692A82
|texte= Influenza vaccines: new developments
}}
| This area was generated with Dilib version V0.6.33. |  |